Houston, TEXAS30 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Houston, TEXAS

Find 30 actively recruiting myalgic encephalomyelitis clinical trials in Houston, TEXAS. Connect with local research sites and explore new treatment options.

30
Active Trials
25
Sponsors
3,019
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Houston

RecruitingHouston, TEXASNCT03947385

Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations o...

341 participants
IDEAYA Biosciences
View Study Details
RecruitingHouston, TEXASNCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...

336 participants
Vivace Therapeutics, Inc
View Study Details
RecruitingHouston, TEXASNCT02710253

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) o...

230 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TEXASNCT06499285

The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)

This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk...

225 participants
Takeda
View Study Details
RecruitingHouston, TEXASNCT03422198

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I...

188 participants
University of Utah
View Study Details
RecruitingHouston, TEXASNCT04594187

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for...

168 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TEXASNCT05267626

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...

159 participants
Aulos Bioscience, Inc.
View Study Details
RecruitingHouston, TEXASNCT06388200

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mut...

150 participants
Ocugen
View Study Details
RecruitingHouston, TEXASNCT04683653

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine t...

100 participants
University of Chicago
View Study Details
RecruitingHouston, TEXASNCT04308512

Care Coordination System for People With Dementia

Dementia, a chronic disease of aging, is characterized by progressive cognitive decline that interferes with independent functioning. The medical, psychological, social and functional sequelae of deme...

100 participants
Bijan Najafi, PhD
View Study Details
RecruitingHouston, TEXASNCT06594991

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or met...

88 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingHouston, TEXASNCT05308264

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)...

86 participants
Rigel Pharmaceuticals
View Study Details
RecruitingHouston, TEXASNCT06627179

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in...

81 participants
Laboratoires Thea
View Study Details
RecruitingHouston, TEXASNCT05319353

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify...

80 participants
Takeda
View Study Details
RecruitingHouston, TEXASNCT06782373

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestati...

78 participants
Swedish Orphan Biovitrum
View Study Details
RecruitingHouston, TEXASNCT05127226

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome....

70 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingHouston, TEXASNCT05371613

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central n...

63 participants
Denali Therapeutics Inc.
View Study Details
RecruitingHouston, TEXASNCT03383575

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth...

63 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TEXASNCT06481592

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer....

60 participants
Iovance Biotherapeutics, Inc.
View Study Details
RecruitingHouston, TEXASNCT05932199

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM. Primary Objectives: The primary objective...

52 participants
Baylor College of Medicine
View Study Details
RecruitingHouston, TEXASNCT05795465

A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subje...

52 participants
GEn1E Lifesciences
View Study Details
RecruitingHouston, TEXASNCT06430385

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

The primary purpose of this study is to evaluate the safety and tolerability of ION440....

48 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingHouston, TEXASNCT06465953

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previ...

48 participants
Institut de Recherches Internationales Servier
View Study Details
RecruitingHouston, TEXASNCT05431270

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in ...

40 participants
Phanes Therapeutics
View Study Details
RecruitingHouston, TEXASNCT07157787

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein cr...

30 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingHouston, TEXASNCT04747431

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment ...

25 participants
Passage Bio, Inc.
View Study Details
RecruitingHouston, TEXASNCT05355272

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD)...

20 participants
Baylor College of Medicine
View Study Details
RecruitingHouston, TEXASNCT06730126

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called l...

15 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingHouston, TEXASNCT05898620

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

This study will evaluate the safety profile of the investigational gene therapy, NGN-401, in females with typical Rett syndrome....

14 participants
Neurogene Inc.
View Study Details
RecruitingHouston, TEXASNCT06064890

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations...

9 participants
AviadoBio Ltd
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Houston

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 30 myalgic encephalomyelitis clinical trials recruiting participants in Houston, TEXAS. These studies are seeking a combined 3,019 participants. Research is being sponsored by IDEAYA Biosciences, Vivace Therapeutics, Inc, M.D. Anderson Cancer Center and 22 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Houston — FAQ

Are there myalgic encephalomyelitis clinical trials in Houston?

Yes, there are 30 myalgic encephalomyelitis clinical trials currently recruiting in Houston, TEXAS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 30 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov